3,750
Views
4
CrossRef citations to date
0
Altmetric
Clinical focus: Current Issues in Venous Thromboembolism - Review

Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients

ORCID Icon
Pages 51-63 | Received 28 Oct 2020, Accepted 12 Jan 2021, Published online: 09 Feb 2021
 
1

ABSTRACT

There is a widely expressed concern about an unmet need for post hospitalization venous thromboembolism (VTE) prophylaxis in medically ill patients, however, physicians and hospitals have been slow to implement this measure. Recommendations against extended VTE prophylaxis in medical patients from the American Society of Hematology (ASH) in 2018 and the withholding of approval of betrixiban by the European Medicines Agency also in 2018 may have been influential in this regard. Furthermore, rivaroxaban the other drug approved for this indication in the U.S has not yet been approved in Europe. In addition, hospital administrators, those monitoring expenses in the U.S, have been reluctant to support a treatment which will mostly involve outpatients. Internal medicine physicians, hospitalists and nursing home physicians have not shared the fervor for post hospital VTE prophylaxis, whether with anticoagulants or aspirin, that their orthopedic surgery colleagues have, particularly in hip and knee arthroplasty. This is despite an increased risk of post hospital discharge thrombosis in both groups of patients. Enter hospitalized patients with COVID-19, a potentially severe medical illness with high hospitalization related thrombosis risk, and questions arise as to whether these medical patients, who are clearly more hypercoagulable during hospitalization than those in previous studies, should warrant post hospital discharge prophylaxis.

Declaration of financial/other relationships

SB is a speaker for Janssen pharmaceuticals and Alexion pharmaceuticals.

A reviewer on this manuscript has disclosed that they have previously received an investigator-initiated research grant and travel grant from Sanofi (manufacturer of enoxaparin). Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Acknowledgments

None stated.

Declaration of interest

No potential conflict of interest was reported by the author.

Additional information

Funding

No funding was received to produce this article.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 708.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.